Inoviq Ltd (AU:IIQ)
ASX:IIQ
Want to see AU:IIQ full AI Analyst Report?
IIQ Stock Chart & Stats
AU$0.40
AU$0.02(3.09%)
At close: 4:00 PM EST
AU$0.40
AU$0.02(3.09%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$0.49
Previous CloseN/A
Volume76.26K
Average Volume (3M)196.06K
Market Cap
AU$44.34M
Enterprise ValueAU$24.43M
Total Cash (Recent Filing)AU$13.80M
Total Debt (Recent Filing)AU$270.31K
Price to Earnings (P/E)―
Beta0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume262,451
30 Day Avg. Volume196,057
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity ratio (0.0225) materially reduces financial distress risk and interest burden. Over 2-6 months this preserves flexibility to fund R&D, pursue partnerships or licensing deals, and navigate commercialization timing without heavy fixed financing costs.
Specialised Exosome PlatformA clear strategic focus on exosome-based diagnostics and research tools creates a high-barrier niche and IP accumulation. This specialization supports durable competitive advantages, attracts collaboration interest from pharma/academia, and aligns with long-term demand for earlier cancer detection.
Diversified Revenue PathwaysA multi-pronged revenue model—research product sales, diagnostic test commercialization, and collaboration/licensing—provides several durable routes to cash. Product sales can sustain recurring revenue while partnerships and milestones offer non-linear funding for development and commercialization.
Bears Say
Revenue DeclineA notable revenue contraction (-17.2% most recent year) signals weakening market traction or commercialization delays. Persistent declines shrink scale, reduce pricing leverage, and limit reinvestment capacity for R&D and go-to-market activities, undermining medium-term growth prospects.
Poor ProfitabilityNegative gross, EBIT and net margins, and a deeply negative ROE indicate the business currently cannot translate sales into sustainable profits. Over months this impairs reinvestment, makes self-funding of trials/commercial launches unlikely, and raises dependence on external funding.
Weak Cash GenerationOngoing negative operating and free cash flows reflect structural cash burn. Even with some alignment between free cash flow and reported earnings, absolute outflows constrain runway and force reliance on dilutive capital raises or partnership financing, limiting execution independence.
Inoviq Ltd News
IIQ FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest share price was AU$0.31 and its highest was AU$0.49 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is AU$44.34M.
When is Inoviq Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inoviq Ltd’s earnings last quarter?
Currently, no data Available
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in AU:IIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IIQ Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$119.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.83%
12-Months-Change
Fundamentals
Return on Equity
-37.14%
Trailing 12-Months
Asset Growth
15.77%
Trailing 12-Months
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---